Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciac629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Christina J Atchison und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council, British Heart Foundation, Wellcome Trust.
Abstract (Originalsprache)
Background
We explore severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow immunoassay (LFIA) performance under field conditions compared to laboratory-based electrochemiluminescence immunoassay (ECLIA) and live virus neutralization.
Methods
In July 2021, 3758 participants performed, at home, a self-administered Fortress LFIA on finger-prick blood, reported and submitted a photograph of the result, and provided a self-collected capillary blood sample for assessment of immunoglobulin G (IgG) antibodies using the Roche Elecsys® Anti-SARS-CoV-2 ECLIA. We compared the self-reported LFIA result to the quantitative ECLIA and checked the reading of the LFIA result with an automated image analysis (ALFA). In a subsample of 250 participants, we compared the results to live virus neutralization.
Results
Almost all participants (3593/3758, 95.6%) had been vaccinated or reported prior infection. Overall, 2777/3758 (73.9%) were positive on self-reported LFIA, 2811/3457 (81.3%) positive by LFIA when ALFA-reported, and 3622/3758 (96.4%) positive on ECLIA (using the manufacturer reference standard threshold for positivity of 0.8 U mL–1). Live virus neutralization was detected in 169 of 250 randomly selected samples (67.6%); 133/169 were positive with self-reported LFIA (sensitivity 78.7%; 95% confidence interval [CI]: 71.8, 84.6), 142/155 (91.6%; 95% CI: 86.1, 95.5) with ALFA, and 169 (100%; 95% CI: 97.8, 100.0) with ECLIA. There were 81 samples with no detectable virus neutralization; 47/81 were negative with self-reported LFIA (specificity 58.0%; 95% CI: 46.5, 68.9), 34/75 (45.3%; 95% CI: 33.8, 57.3) with ALFA, and 0/81 (0%; 95% CI: 0, 4.5) with ECLIA.
Conclusions
Self-administered LFIA is less sensitive than a quantitative antibody test, but the positivity in LFIA correlates better than the quantitative ECLIA with virus neutralization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, Imperial College London, London, United Kingdom.
- Imperial College Healthcare NHS Trust, London, United Kingdom.
- Department of Infectious Disease, Imperial College London, London, United Kingdom.
- Department of Bioengineering, Imperial College London, London, United Kingdom.
- London Centre for Nanotechnology & Division of Medicine, University College London, London, United Kingdom.
- Division of Medicine, University College London, London, United Kingdom.
ORCID-Profile: Paul Elliott
Förderung
- Medical Research Council
- British Heart Foundation
- Wellcome Trust
- Department of Health and Social Care
- National Institute for Health Research
- NIHR Professorship
- Abdul Latif Jameel Institute for Disease and Emergency Analytics
- Imperial College London
Zitieren
APA
Atchison, C. J., Moshe, M., Brown, J. C., Whitaker, M., Wong, N. C. K., Bharath, A. A., McKendry, R. A., Darzi, A., Ashby, D., Donnelly, C. A., Riley, S., Elliott, P., Barclay, W. S., Cooke, G. S., & Ward, H. (2023). Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac629
Vancouver
Atchison CJ, Moshe M, Brown JC, Whitaker M, Wong NCK, Bharath AA, et al. Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac629
BibTeX
@article{Atchison2023,
author = {Atchison, Christina J and Moshe, Maya and Brown, Jonathan C and Whitaker, Matthew and Wong, Nathan C K and Bharath, Anil A and McKendry, Rachel A and Darzi, Ara and Ashby, Deborah and Donnelly, Christl A and Riley, Steven and Elliott, Paul and Barclay, Wendy S and Cooke, Graham S and Ward, Helen},
title = {Validity of Self-testing at Home With Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Detection by Lateral Flow Immunoassay},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciac629}
}
EUVIMED